BioNTech reports positive COVID-19 vaccine data with Pfizer, receives $2 billion order from US Govt
BioNTech SE (BNTX) reported positive early data for its COVID-19 vaccine candidate, BNT162b1. The company is collaborating with Pfizer (PFE) for developing this vaccine candidate. BNT162b1 is a lipid nanoparticle formulated, nucleoside-modified messenger RNA encoding a SARS-CoV-2 receptor binding domain (RBD) antigen.
Phase I/II of the study is an open-label, non-randomized, non-placebo-controlled, dose-escalation trial. It is being conducted in Germany and involves 60 healthy participants aged between 18 and 55 years. Out of these, 12 participants